查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1850576

癌症/腫瘤分析市場按技術、產品類型、應用和最終用戶分類 - 全球預測 2025-2032 年

Cancer/Tumor Profiling Market by Technology, Product Type, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，癌症/腫瘤分析市場規模將達到 525.5 億美元，複合年成長率為 19.34%。

主要市場統計數據
基準年 2024 127.7億美元
預計年份：2025年 152.9億美元
預測年份：2032年 525.5億美元
複合年成長率 (%) 19.34%

對腫瘤譜分析進行策略性介紹，闡述技術融合、臨床效用和相關人員獎勵，以指導高階主管決策。

本執行摘要全面概述了不斷發展的腫瘤譜分析領域，涵蓋技術進步、監管現狀、臨床效用和商業策略。其目的是為高階主管、臨床負責人、研發主管和策略投資者提供清晰、實用且全面的視角，幫助他們了解影響腫瘤診斷和轉化醫學發展方向的關鍵因素。本書透過整合跨領域趨勢和實際應用，力求簡化複雜性，並為近期決策提供連貫的基礎。

引言部分將腫瘤譜分析定位為一個融合的生態系統，而非僅僅是一系列檢測技術的集合，其中基因組學、蛋白質組學和資訊學與臨床工作流程相互交織。引言重點闡述了檢測方法的選擇、資料管理和終端用戶整合如何共同決定臨床價值鏈。此外，引言還揭示了獎勵的動機——從支付方和醫院系統到製藥合作夥伴和學術中心——為後續章節奠定了基礎，這些章節將探討市場變化、政策影響、細分促進因素和區域差異。

最後，引言部分概述了貫穿整個報告的分析方法，強調證據綜合、專家三角驗證以及注重實際應用而非純粹的學術探討。這種導向使讀者能夠迅速將洞見轉化為優先行動，例如最佳化籌資策略、完善產品藍圖以及使臨床檢驗項目與新標準接軌。

對腫瘤譜分析根本性變革的全面分析，包括技術融合、監管協調和整合的臨床工作流程。

腫瘤分析領域正經歷一系列變革性轉變，其驅動力包括技術的成熟、臨床管道的改變以及對個人化醫療日益成長的重視。定序通量和準確性的提高降低了技術門檻，使得複雜檢測方法在學術界和社區醫療機構中廣泛應用。同時，生物資訊流程和雲端基礎平台的改進正從多模態資料中挖掘出具有臨床指導意義的訊息，從而重塑診斷流程和治療決策。

同時，支付方和監管機構也越來越重視臨床效用的論證和分析有效性的保障。這種監管重點正在加速診斷公司、臨床實驗室和製藥企業之間的合作，以共同開發伴隨診斷並產生基於結果的證據。此外，將液態切片方法和微量殘存疾病監測納入常規實踐，正在拓展腫瘤譜分析的臨床應用範圍，使其從初始診斷延伸至監測和治療選擇。

此外，供應鏈韌性和平台整合正在影響醫院、參考實驗室和研究中心的採購行為。這種結構性轉變有利於整合儀器、檢驗的耗材和強大的軟體生態系統的整合解決方案。因此，能夠展現端到端價值、互通性和可擴展服務模式的供應商正在贏得市場。摘要，市場格局正在從孤立的檢測轉向支持適應性臨床管理和協作證據產生的整合診斷策略。

深入檢驗近期美國關稅如何重塑腫瘤分析領域的供應鏈、籌資策略與臨床應用。

美國新關稅的實施為腫瘤分析生態系統中的相關人員帶來了營運和策略方面的考量，影響到供應鏈的採購、定價和供應商的選擇。進口設備和試劑的關稅可能會影響採購週期，並促使獎勵轉向本地生產和供應商多角化。因此，臨床實驗室和醫院正在重新評估其供應商合約和庫存策略，以應對成本波動，同時確保患者檢測的連續性。

此外，主導調整正促使製造商和經銷商重新思考其商業模式。一些供應商正在探索區域生產基地、與國內供應商建立策略聯盟以及建立垂直整合的供應鏈，以降低風險。這種轉變通常包括重新評估產品系列，優先生產適合本地生產的高利潤耗材，並最佳化物流以最大限度地降低到岸成本的影響。同時，在硬體價格承壓的情況下，服務型產品和軟體訂閱模式也成為維持收入穩定的重要途徑。

從臨床角度來看，關稅的間接影響，例如設備部署延遲和試劑供應受限，可能會影響檢測時間表、檢測註冊以及新檢測方法的推廣。因此，相關人員正日益將供應鏈風險評估納入臨床專案規劃和採購管治中。簡而言之，價值鏈正在推動對整個價值鏈中腫瘤分析策略的韌性和本地化進行重新評估，鼓勵製造商、經銷商和最終用戶之間採取協作方式，以維持創新和患者可及性。

全面的細分揭示了技術類別、產品類型、臨床應用和最終用戶如何以獨特的方式影響診斷策略和應用。

對腫瘤分析領域進行細緻的細分，可以揭示在技術、產品類型、應用和最終用戶方面，創新和應用壓力最為顯著的領域。按技術分類，該細分領域包括常規PCR、數位PCR、FISH、IHC、微陣列、下一代定序和即時PCR，每種技術都具有獨特的分析優勢和操作流程。在FISH中，染色體計數探針、拷貝數變異和融合基因檢測仍然是評估細胞遺傳學和結構變異的核心；而IHC技術，例如直接IHC、間接IHC和組織微陣列，仍然是組織病理學工作流程中蛋白質表現和受體分析的基礎。即使定序正在取代一些傳統應用，微陣列方法，例如比較基因組雜合反應、表現譜分析和SNP基因型鑒定，仍在特定的研究和診斷領域中發揮作用。

次世代定序儀依定序深度、廣度和臨床應用性，可分為標靶定序、轉錄組定序、全外EXOME定序和全基因組定序。靶向定序又可細分為基於擴增子的方法和雜交捕獲方法，二者在樣本量要求、靈敏度和設計靈活性方面存在差異。即時螢光定量PCR仍是定量快速檢測的主要手段，並根據其成本、多重檢測能力和特異性，分為基於染料的化學方法和基於探針的化學方法。

依產品類型，市場可細分為耗材和試劑、儀器以及軟體服務。耗材和試劑包括抗體、PCR試劑、探針和定序試劑，這些是持續的收入來源，並且與平台應用密切相關。螢光顯微鏡、質譜儀、微陣列掃描儀、PCR儀和定序儀等設備屬於資本投資，決定了實驗室的容量和通量。生物資訊軟體、雲端平台、諮詢服務和資料管理系統等軟體和服務對於價值提案的重要性日益凸顯，因為它們能夠實現結果解讀、符合法規要求以及與臨床工作流程的無縫整合。

這些應用涵蓋乳癌、大腸癌、肺癌和攝護腺癌，每種癌症都需要量身定做的檢測組合和驗證策略。乳癌計畫通常著重於基因表現分析、基因突變檢測、蛋白質體學分析和受體譜分析，以指導治療選擇和預後判斷。大腸直腸癌計畫則依賴表觀遺傳譜分析、微衛星不穩定性檢測和突變分析來指導篩檢和治療決策。肺癌譜分析優先考慮微小殘留病灶監測、分子敏感性檢測和治療方法選擇，從而指導標靶治療和監測策略。前列腺癌工作流程則採用拷貝數變異分析、融合基因檢測和基因表現分析來最佳化風險分層和管理流程。

最後，終端用戶細分突顯了腫瘤譜分析應用的多樣化環境，包括診斷實驗室、醫院和診所、製藥和生物製藥公司以及研究和學術機構。診斷實驗室（無論是用於臨床檢測還是參考檢測）優先考慮的是檢測通量、單次檢測成本和標準化工作流程。醫院和診所則需要在現場診斷和與中心實驗室合作之間取得平衡，並優先考慮週轉時間和臨床整合。製藥和生物製藥公司（涵蓋臨床檢測、伴隨診斷服務和藥物開發）尋求可擴展且檢驗的檢測方法，以支持臨床檢測終點和監管申報。研究和學術機構（包括生物技術研究中心、政府研究機構和大學實驗室）優先考慮的是方法的靈活性、探索性檢測以及與臨床合作夥伴的合作。綜上所述，這些細分揭示了腫瘤譜分析生態系統中不同的需求促進因素、投資重點和商業化路徑。

區域觀點著重分析主要全球市場中不同的採用模式、監管動態和基礎設施優先事項

區域動態對腫瘤譜分析領域的技術應用、報銷模式和合作研究計畫有顯著影響。在美洲，對精準腫瘤學基礎設施的投資以及商業實驗室與醫院系統之間的緊密整合，正在加速高性能測序和液態切片應用的普及。該地區的臨床和商業生態系統優先考慮快速檢驗週期和與製藥公司建立合作關係，以支持生物標記主導的臨床試驗和伴隨診斷的開發，同時也強調與支付方的合作，以證明其臨床效用。

同時，歐洲、中東和非洲是異質性環境，其法律規範、國家衛生優先事項和實驗室能力差異巨大。中東和北非市場可能會優先考慮能力建構和技術轉讓，以擴大診斷覆蓋範圍。在全部區域，學術聯盟和跨國合作在標準化檢測驗證和促進跨境研究活動方面發揮關鍵作用。

在亞太地區，基因組學基礎設施的快速投資、臨床檢測活動的不斷擴展以及對本土診斷的日益重視，正在推動獨特的應用模式。該地區許多國家正在推進國家基因組學舉措，並促進官民合作關係以擴大分子診斷的應用。因此，供應商正在調整其商業策略，以符合當地的監管要求、定價預期和能力建構方案。總而言之，這些區域性洞察凸顯了製定區域差異化打入市場策略、針對當地相關人員客製化的證據計劃以及能夠應對該地區獨特供應鏈和監管現實的營運模式的必要性。

市場情報顯示，領先的製造商、試劑專家和軟體創新者正在建立夥伴關係，以重塑腫瘤分析領域的競爭優勢。

在儀器、耗材和軟體生態系統中，主要企業扮演著不同的角色，它們的策略選擇正在塑造腫瘤分析領域的競爭動態和客戶期望。現有定序平台供應商持續投資於通量、準確性和工作流程自動化，以支援臨床級檢測；而試劑和耗材專家則專注於檢測驗證、批間一致性和供應的連續性。同時，規模較小的創新企業則透過細分應用、檢測專業化以及能夠簡化結果解讀和報告的整合軟體來實現差異化競爭。

診斷公司與製藥公司之間的夥伴關係仍然是加速伴隨診斷開發和共同產生臨床證據的核心策略。這些合作通常包括聯合檢測驗證、數據平台共用和監管申報，以加速臨床試驗進程。此外，一些儀器製造商正在擴展其服務範圍，包括培訓、維護和遠端監控，以降低臨床實驗室和醫院網路的運作門檻。提供可擴展生物資訊學、安全雲端平台和符合監管要求的資料管理系統的軟體供應商正變得越來越重要，因為它們彌合了原始資料生成和臨床決策支援之間的差距。

因此，提供檢驗、可互通的解決方案（包括硬體、耗材和解讀服務）的能力是競爭優勢的關鍵驅動力。能夠證明自身擁有嚴格的臨床檢驗、穩健的供應鏈以及清晰的合規路徑的公司，更有可能贏得與參考實驗室、醫院系統和製藥公司的長期合約。這正在推動生態系統向協作模式轉變，在這種模式下，供應商、臨床機構和生命科學合作夥伴共同創造創新，從而加速技術應用並維持其臨床相關性。

為領導者提供行動建議，以加強能夠促進韌性、證據產生、互通性和持續採用的商業模式。

產業領導者應優先考慮一系列切實可行的措施，以增強韌性、加速臨床應用並最大化商業性回報。首先，應優先考慮整合解決方案，將經過驗證的儀器、穩定的試劑供應和強大的解讀軟體結合。其次，應投資於符合支付方需求和臨床終點的證據產生策略。第三，應制定靈活的供應鏈策略，包括區域生產、策略夥伴關係和庫存管理方法，以降低關稅和地緣政治風險。

此外，我們將透過建立以金額為準的合約和績效保證，使商業性條款與已證實的臨床結果一致，從而消除支付方的疑慮並支持更廣泛的應用。我們將透過強調互通性和基於標準的數據交換，並促進其與電子健康記錄和腫瘤委員會的整合，來推動臨床醫生採用這些技術。此外，我們將與學術中心和製藥贊助商建立合作夥伴關係，共同開發檢測方法，加速驗證並擴展臨床應用案例。最後，我們將建立模組化服務和可擴展的支援模式，涵蓋培訓、維護以及生物資訊訂閱服務等各個方面，以創造持續的收入來源並深化客戶關係。

落實這些優先事項不僅有助於機構應對短期挑戰，還能隨著腫瘤譜分析融入個人化腫瘤診療流程，創造長期價值。為此，領導者必須保持靈活應變，密切注意政策和報銷政策的變化，並持續將臨床回饋融入產品和服務改進中。

切實可行的見解源自於嚴謹的調查方法，結合了系統性的文獻回顧、專家訪談和交叉檢驗的證據綜合。

本次高階主管分析的調查方法結合了定性和定量證據綜合、主要相關人員調查以及結構化專家檢驗。該方法首先系統地回顧了同行評審文獻、監管指導文件和臨床實踐標準，以確定技術能力、驗證要求和臨床效用框架。此外，還對實驗室主任、腫瘤學家、生物資訊負責人、採購專家和公司高管進行了有針對性的訪談，以了解實施實踐和策略重點。

二次檢驗包括交叉參考供應商技術規格、公開的監管文件和臨床試驗註冊訊息，以確保分析方案與當前產品功能和證據產生管道相符。我們運用三角測量法來調和商業性定位與臨床實務之間的差異，特別關注工作流程整合、週轉時間限制和資料管治需求。在適用情況下，我們使用用例和匿名範例來說明實際應用，同時避免洩露專有資訊。

最後，我們運用情境分析來探討政策轉變、供應鏈中斷和技術曲折點可能如何影響相關人員的行為。在整個過程中，我們始終強調假設的透明度、供應來源的可複製性，以及將技術細節轉化為適用於經營團隊決策的可操作建議。

簡明結論總結了合作、證據完整性和靈活策略對於實現精準腫瘤學益處的重要性。

總之，腫瘤譜分析正從單一的實驗室檢測向整合的診斷生態系統轉型，該生態系統融合了先進的分析技術、可擴展的工作流程和循證的商業化策略。定序、數位檢測和生物資訊學的技術進步正在拓展其臨床應用，使其從診斷延伸至監測和治療選擇，而監管機構和支付方的監督則鼓勵更嚴謹的證據生成和協作檢驗模式。因此，供應商、臨床實驗室和生命科學合作夥伴必須在互通性、品質標準和真實世界結果方面達成一致，才能真正實現精準腫瘤學的願景。

供應鏈壓力和政策變化所帶來的累積效應凸顯了彈性籌資策略和在適當情況下進行在地化生產的重要性。此外，不同地區在技術應用和法律規範的差異，要求制定能夠反映當地臨床優先事項和基礎設施能力的客製化市場策略。能夠提供經過驗證的端到端解決方案並展現明確臨床效益的公司，將有能力主導下一階段的技術應用。

總而言之，未來發展的關鍵在於診斷服務提供者、臨床相關人員和研究機構之間的持續合作，從而將技術能力轉化為可衡量的患者獲益。透過專注於實證醫學、營運整合和策略夥伴關係，各機構可以加速癌症診斷和治療的實質改善。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 將多體學分析技術與人工智慧驅動的分析結合，應用於個人化腫瘤治療方案製定
  • 拓展液態生物檢體檢測技術，以實現對腫瘤特異性基因突變的非侵入性檢測和即時監測
  • 利用單細胞定序平台揭示腫瘤內異質性並識別新的治療標靶
  • 數位病理學的出現，結合深度學習演算法，實現了腫瘤形態學和生物標記定量分析的自動化。
  • 利用複雜的基因組特徵開發用於標靶治療選擇的綜合伴隨診斷
  • 分散式檢查工作流程的成長，包括遠端樣本採集和遠端醫療輔助腫瘤分析服務
  • 免疫分析技術的進步可用於預測患者對查核點抑制劑和細胞療法的反應
  • 整合來自人群登記處的真實世界證據將提高腫瘤譜分析在臨床實踐中的效用。
  • 旨在簡化全球先進腫瘤基因檢測核准流程的監管協調工作

第6章美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 按技術分類的癌症/腫瘤分析市場

  • 常規PCR
  • 數位PCR
  • FISH
    • 染色體計數探針
    • 拷貝編號變體
    • 融合基因檢測
  • IHC
    • 直接免疫組織化學
    • 間接免疫組織化學
    • 組織微陣列
  • 微陣列
    • 比較基因組雜合反應
    • 表達譜分析
    • SNP基因基因型鑒定
  • 下一代定序
    • 目標序列
      • 基於擴增子的
      • 混合捕獲
    • 轉錄組定序
    • 全外EXOME定序
    • 全基因組序列分析
  • 即時PCR
    • 染料
    • 探針基座

9. 按產品類型分類的癌症/腫瘤分析市場

  • 消耗性試劑
    • 抗體
    • PCR試劑
    • 探測
    • 定序試劑
  • 裝置
    • 螢光顯微鏡
    • 質譜儀
    • 微陣列掃描儀
    • PCR設備
    • 序列器
  • 軟體和服務
    • 生物資訊軟體
    • 雲端平台
    • 諮詢服務
    • 資料管理系統

第10章 按應用分類的癌症/腫瘤分析市場

  • 乳癌
    • 基因表現分析
    • 基因突變檢測
    • 蛋白質體分析
    • 受體譜分析
  • 大腸直腸癌
    • 表觀遺傳譜分析
    • MSI 測試
    • 突變分析
  • 肺癌
    • 微量殘存疾病監測
    • 分子藥敏試驗
    • 治療方法方案
  • 攝護腺癌
    • 拷貝數變異分析
    • 融合檢測
    • 基因表現分析

第11章 以最終用戶分類的癌症/腫瘤分析市場

  • 診斷實驗室
    • 臨床實驗室
    • 參考實驗室
  • 醫院診所
    • 腫瘤學
    • 病理實驗室
  • 製藥和生物製藥公司
    • 臨床實驗室
    • 伴隨診斷服務
    • 藥物開發部
  • 研究和學術機構
    • 生物技術研究中心
    • 政府研究所
    • 大學實驗室

12. 各地區癌症/腫瘤分析市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 按組別分類的癌症/腫瘤分析市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國癌症/腫瘤分析市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Thermo Fisher Scientific Inc.
    • Illumina, Inc.
    • F. Hoffmann-La Roche Ltd
    • QIAGEN NV
    • Agilent Technologies, Inc.
    • Bio-Rad Laboratories, Inc.
    • PerkinElmer, Inc.
    • Guardant Health, Inc.
    • Natera, Inc.
    • NeoGenomics, Inc.
Product Code: MRR-374DB5A06C7F

The Cancer/Tumor Profiling Market is projected to grow by USD 52.55 billion at a CAGR of 19.34% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 12.77 billion
Estimated Year [2025] USD 15.29 billion
Forecast Year [2032] USD 52.55 billion
CAGR (%) 19.34%

Strategic introduction to tumor profiling that frames technological convergence, clinical utility, and stakeholder incentives to guide executive decision-making

This executive summary introduces a comprehensive perspective on the evolving tumor profiling landscape, synthesizing technological advances, regulatory dynamics, clinical utility, and commercial strategies. The purpose is to equip senior executives, clinical leaders, R&D heads, and strategic investors with a clear and actionable synthesis of the forces shaping diagnostic and translational oncology priorities. By consolidating cross-disciplinary trends and pragmatic implications, the document aims to reduce complexity and provide a coherent foundation for near-term decision making.

The introduction frames tumor profiling not merely as a set of laboratory techniques but as a convergent ecosystem where genomics, proteomics, and informatics intersect with clinical workflows. It highlights how assay selection, data management, and end-user integration collectively determine the clinical value chain. Moreover, the narrative clarifies stakeholder incentives-from payers and hospital systems to pharma partners and academic centers-thereby establishing the context for subsequent sections that examine market shifts, policy influences, segmentation drivers, and regional nuances.

Finally, the introduction outlines the analytical approach used across the report, emphasizing evidence synthesis, expert triangulation, and a focus on practical implications rather than purely academic reviews. This orientation ensures readers can rapidly translate insights into prioritized actions, whether optimizing procurement strategies, refining product roadmaps, or aligning clinical validation programs with emerging standards.

Comprehensive analysis of fundamental shifts transforming tumor profiling including technology convergence, regulatory alignment, and integrated clinical workflows

The tumor profiling landscape is experiencing a set of transformative shifts driven by technological maturation, changing clinical pathways, and a heightened emphasis on personalized medicine. Advances in sequencing throughput and precision are reducing technical barriers and enabling broader adoption of complex assays in both academic and community settings. At the same time, improvements in bioinformatics pipelines and cloud-based platforms are unlocking clinically actionable insights from multimodal data, which in turn is reshaping diagnostic workflows and therapeutic decision points.

Concurrently, payers and regulators are increasingly focused on demonstrating clinical utility and ensuring analytical validity, which is prompting companies to align evidence generation with real-world clinical endpoints. This regulatory emphasis is accelerating partnerships between diagnostics companies, clinical laboratories, and pharmaceutical sponsors to co-develop companion diagnostics and generate outcomes-based evidence. Furthermore, the integration of liquid biopsy approaches and minimal residual disease monitoring into routine care pathways is expanding the clinical use cases for tumor profiling beyond initial diagnosis to surveillance and therapy selection.

In addition, supply chain resilience and platform consolidation are influencing procurement behavior among hospitals, reference laboratories, and research centers. These structural shifts favor integrated solutions that combine instruments, validated consumables, and robust software ecosystems. As a result, vendors that can demonstrate end-to-end value, interoperability, and scalable service models are gaining a competitive edge. In summary, the landscape is moving from isolated assays toward integrated diagnostic strategies that support adaptive clinical management and collaborative evidence generation.

In-depth examination of how recent United States tariff measures are reshaping supply chains, procurement strategies, and clinical deployment across tumor profiling

The imposition of new tariff measures in the United States has introduced operational and strategic considerations for stakeholders across the tumor profiling ecosystem, affecting supply chain sourcing, procurement pricing, and vendor selection. Tariffs on imported instruments and reagents can influence procurement timetables and create incentives for localized manufacturing or supplier diversification. As a result, clinical laboratories and hospitals are reassessing vendor contracts and inventory strategies to buffer against cost volatility while maintaining continuity of patient testing.

Moreover, tariff-driven adjustments are prompting manufacturers and distributors to reconsider their commercial models. Some vendors are exploring regional production hubs, strategic partnerships with domestic suppliers, and vertically integrated supply chains to mitigate exposure. This shift often involves re-evaluating product portfolios, prioritizing high-margin consumables for localized production, and optimizing logistics to minimize landed cost impacts. In parallel, service-oriented offerings and software subscriptions are being emphasized as ways to preserve revenue stability amid hardware pricing pressures.

From a clinical perspective, the indirect consequences of tariffs-such as delayed instrument deployments or constrained reagent availability-can affect study timelines, trial enrollment, and the rollout of new assays. Therefore, stakeholders are increasingly incorporating supply chain risk assessments into clinical program planning and procurement governance. In short, tariffs have catalyzed a broader reassessment of resilience and localization strategies across the tumor profiling value chain, encouraging collaborative approaches between manufacturers, distributors, and end users to sustain innovation and patient access.

Comprehensive segmentation insight revealing how technology categories, product types, clinical applications, and end users uniquely shape diagnostic strategies and adoption

A careful segmentation of the tumor profiling domain illuminates where innovation and adoption pressures are most pronounced across technology, product type, application, and end user. Based on technology, the field encompasses Conventional PCR, Digital PCR, FISH, IHC, Microarray, Next Generation Sequencing, and Real Time PCR, each offering distinct analytical strengths and operational footprints. Within FISH, chromosome enumeration probes, copy number variation, and fusion gene detection remain central to cytogenetic and structural variant assessments, while IHC modalities such as direct IHC, indirect IHC, and tissue microarray continue to underpin protein expression and receptor profiling in histopathology workflows. Microarray approaches, including comparative genomic hybridization, expression profiling, and SNP genotyping, still play roles in certain research and diagnostic niches even as sequencing displaces some legacy applications.

Next Generation Sequencing is itself stratified across targeted sequencing, transcriptome sequencing, whole exome sequencing, and whole genome sequencing, reflecting a tiered approach to depth, breadth, and clinical applicability. Targeted sequencing further divides into amplicon-based and hybrid capture methods, which differ in input requirements, sensitivity, and design flexibility. Real Time PCR remains a workhorse for quantitation and rapid assays, split between dye-based and probe-based chemistries that trade off cost, multiplexing capability, and specificity.

Turning to product type, the market is delineated into consumables and reagents, instruments, and software and services. Consumables and reagents-encompassing antibodies, PCR reagents, probes, and sequencing reagents-drive recurring revenue and are tightly coupled to platform adoption. Instruments, from fluorescence microscopes and mass spectrometers to microarray scanners, PCR instruments, and sequencers, represent capital investments that influence laboratory capability and throughput. Software and services, including bioinformatics software, cloud platforms, consultation services, and data management systems, are increasingly decisive in value propositions because they enable interpretation, regulatory compliance, and seamless integration with clinical workflows.

Applications span breast cancer, colorectal cancer, lung cancer, and prostate cancer, with each indication demanding tailored assay portfolios and validation strategies. Breast cancer programs commonly emphasize gene expression profiling, genetic mutation detection, proteomic profiling, and receptor profiling to inform treatment choice and prognosis. Colorectal cancer programs rely on epigenetic profiling, microsatellite instability testing, and mutation analysis to inform screening and therapeutic decisions. Lung cancer profiling prioritizes minimal residual disease monitoring, molecular susceptibility testing, and therapy selection to guide targeted therapies and monitoring strategies. Prostate cancer workflows employ copy number variation analysis, fusion detection, and gene expression analysis to refine risk stratification and management pathways.

Finally, the end-user segmentation highlights the diverse settings where tumor profiling is deployed, including diagnostic laboratories, hospitals and clinics, pharma and biopharma companies, and research and academic institutes. Diagnostic laboratories, whether clinical or reference, focus on throughput, cost per test, and standardized workflows. Hospitals and clinics balance on-site diagnostics with centralized laboratory partnerships and place a premium on turnaround time and clinical integration. Pharma and biopharma entities, spanning clinical trial units, companion diagnostic services, and drug development divisions, seek scalable, validated assays that support trial endpoints and regulatory submissions. Research and academic institutes, including biotech research centers, government research institutes, and university research labs, emphasize methodological flexibility, exploratory assays, and collaboration with clinical partners. Collectively, these segmentation lenses reveal differentiated demand drivers, investment priorities, and commercialization pathways across the tumor profiling ecosystem.

Nuanced regional perspective highlighting divergent adoption patterns, regulatory dynamics, and infrastructure priorities across major global markets

Regional dynamics exert a major influence on technology adoption, reimbursement models, and collaborative research initiatives within the tumor profiling landscape. In the Americas, investment in precision oncology infrastructure and strong integration between commercial laboratories and hospital systems have accelerated the adoption of high-throughput sequencing and liquid biopsy applications. This region's clinical and commercial ecosystems prioritize rapid validation cycles and partnerships with pharmaceutical sponsors to support biomarker-driven trials and companion diagnostic development, while also emphasizing payer engagement to demonstrate clinical utility.

Meanwhile, Europe, the Middle East & Africa presents a heterogeneous environment where regulatory frameworks, national health priorities, and laboratory capacities vary significantly. European regulatory harmonization efforts and centralized health technology assessment processes shape reimbursement pathways and clinical adoption, whereas markets in the Middle East and Africa may prioritize capacity building and technology transfer to expand diagnostic coverage. Across this region, academic consortia and pan-national collaborations are playing important roles in standardizing assay validation and enabling cross-border research efforts.

In the Asia-Pacific region, rapid investments in genomic infrastructure, expanding clinical trial activity, and an increasing emphasis on domestically produced diagnostics are driving distinct adoption patterns. Many countries in this region are advancing national genomics initiatives and fostering public-private partnerships to scale molecular diagnostics. Consequently, vendors are adapting commercial strategies to accommodate local regulatory requirements, pricing expectations, and capacity-building programs. Taken together, these regional insights underscore the need for geographically differentiated go-to-market strategies, evidence plans tailored to local stakeholders, and operational models that address region-specific supply chain and regulatory realities.

Market intelligence on how leading manufacturers, reagent specialists, and software innovators are forming partnerships and reshaping competitive advantage in tumor profiling

Leading companies play distinct roles across instruments, consumables, and software ecosystems, and their strategic choices are shaping competitive dynamics and customer expectations within tumor profiling. Established sequencing platform providers continue to invest in throughput, accuracy, and workflow automation to support clinical-grade assays, while reagent and consumable specialists focus on assay validation, lot-to-lot consistency, and supply continuity. At the same time, smaller innovators are differentiating through niche applications, assay specialization, and integrated software that streamlines interpretation and reporting.

Partnerships between diagnostics firms and pharmaceutical companies remain a central tactic to accelerate companion diagnostic development and co-generated clinical evidence. These collaborations frequently involve joint assay validation, shared data platforms, and coordinated regulatory filings to reduce time to clinic. Additionally, several instrument manufacturers are expanding their service portfolios to include training, maintenance, and remote monitoring to reduce operational barriers for clinical laboratories and hospital networks. Software vendors that deliver scalable bioinformatics, secure cloud platforms, and regulatory-ready data management systems are increasingly influential because they bridge raw data generation with clinical decision support.

Competitive advantage is therefore driven by an ability to offer validated, interoperable solutions that integrate hardware, consumables, and interpretation services. Companies that can demonstrate rigorous clinical validation, robust supply chains, and a clear pathway for regulatory compliance are better positioned to win long-term contracts with reference labs, hospital systems, and pharma partners. In this context, the ecosystem is shifting toward collaborative models where innovation is co-created across vendors, clinical institutions, and life sciences partners to accelerate adoption and maintain clinical relevance.

Actionable recommendations for leaders to strengthen resilience, evidence generation, interoperability, and commercial models that drive sustained adoption

Industry leaders should pursue a set of actionable priorities designed to strengthen resilience, accelerate clinical adoption, and maximize commercial returns. First, prioritize integrated solutions that combine validated instruments, consistent reagent supplies, and robust interpretive software, because customers increasingly reward vendors that reduce operational complexity and regulatory burden. Second, invest in evidence generation strategies that align with payer requirements and clinical endpoints, as real-world outcomes and prospective clinical validation remain decisive for reimbursement and guideline inclusion. Third, develop flexible supply chain strategies that include regional production, strategic partnerships, and inventory management practices to mitigate tariff-driven and geopolitical risks.

Furthermore, create value-based contracting and performance guarantees that align commercial terms with demonstrated clinical outcomes, which will help bridge payer skepticism and support broader access. Emphasize interoperability and standards-based data exchange to facilitate integration into electronic health records and tumor boards, thereby increasing clinician uptake. Additionally, cultivate collaborative partnerships with academic centers and pharma sponsors to co-develop assays, which accelerates validation and expands clinical use cases. Finally, build modular service offerings and scalable support models-ranging from training and maintenance to bioinformatics subscription services-to create recurring revenue streams and deepen customer relationships.

By executing these priorities, organizations can not only navigate near-term disruptions but also position themselves to capture long-term value as tumor profiling becomes more embedded in personalized oncology pathways. In doing so, leaders should remain adaptive, monitor policy and reimbursement shifts, and continuously translate clinical feedback into product and service improvements.

Robust research methodology combining systematic literature review, expert interviews, and cross-validated evidence synthesis to underpin actionable insights

The research methodology underpinning this executive analysis combines qualitative and quantitative evidence synthesis, primary stakeholder interviews, and structured validation with subject matter experts. The approach began with a systematic review of peer-reviewed literature, regulatory guidance documents, and clinical practice standards to identify technological capabilities, validation requirements, and clinical utility frameworks. This desk research was complemented by targeted interviews with laboratory directors, oncologists, bioinformatics leaders, procurement specialists, and commercial executives to capture implementation realities and strategic priorities.

Secondary validation included cross-referencing vendor technical specifications, publicly available regulatory filings, and clinical trial registries to ensure the analytical narrative aligned with current product capabilities and evidence generation pathways. Triangulation techniques were applied to reconcile differences between commercial positioning and clinical practice, with particular attention to workflow integration, turnaround time constraints, and data governance needs. Where applicable, case studies and anonymized examples were used to illustrate practical implications without disclosing proprietary details.

Finally, the methodology incorporated scenario analysis to explore how policy shifts, supply chain disruptions, and technological inflection points might influence stakeholder behavior. Throughout the process, emphasis was placed on transparency of assumptions, reproducibility of sources, and the translation of technical detail into operational recommendations suitable for executive decision-making.

Concise conclusion that synthesizes the imperative for collaboration, evidence alignment, and resilient strategies to realize precision oncology benefits

In conclusion, tumor profiling is transitioning from discrete laboratory assays to integrated diagnostic ecosystems that combine advanced analytics, scalable workflows, and evidence-aligned commercialization strategies. Technological advances in sequencing, digital assays, and bioinformatics are expanding clinical applications from diagnosis to monitoring and therapy selection, while regulatory and payer scrutiny is encouraging more rigorous evidence generation and collaborative validation models. Consequently, vendors, clinical laboratories, and life sciences partners must align on interoperability, quality standards, and real-world outcomes to realize the promise of precision oncology.

The cumulative effect of supply chain pressures and policy changes underscores the importance of resilient procurement strategies and localized manufacturing where appropriate. Moreover, regional variations in adoption and regulatory frameworks require tailored market approaches that reflect local clinical priorities and infrastructure capabilities. Companies that can offer validated, end-to-end solutions and demonstrate clear clinical benefit are positioned to lead the next phase of adoption.

Overall, the path forward depends on sustained collaboration between diagnostics providers, clinical stakeholders, and research institutions to translate technological capability into measurable patient impact. By focusing on evidence, operational integration, and strategic partnerships, organizations can accelerate meaningful improvements in cancer diagnosis and management.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of multi-omic profiling techniques combined with AI-driven analytics in personalized oncology treatment planning
  • 5.2. Expansion of liquid biopsy assays enabling non-invasive detection and monitoring of tumor-specific genetic alterations in real time
  • 5.3. Adoption of single-cell sequencing platforms to uncover intratumoral heterogeneity and identify novel therapeutic targets
  • 5.4. Emergence of digital pathology coupled with deep learning algorithms for automated tumor morphology and biomarker quantification
  • 5.5. Development of comprehensive companion diagnostics for targeted therapy selection based on complex genomic signatures
  • 5.6. Growth of decentralized testing workflows incorporating remote sample collection and telemedicine-supported tumor profiling services
  • 5.7. Advances in immunoprofiling technologies for predicting patient response to checkpoint inhibitors and cellular therapies
  • 5.8. Implementation of real-world evidence from population-based registries to refine tumor profiling utility in clinical practice
  • 5.9. Regulatory harmonization efforts aimed at streamlining global approval pathways for advanced tumor profiling assays

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cancer/Tumor Profiling Market, by Technology

  • 8.1. Conventional PCR
  • 8.2. Digital PCR
  • 8.3. FISH
    • 8.3.1. Chromosome Enumeration Probes
    • 8.3.2. Copy Number Variation
    • 8.3.3. Fusion Gene Detection
  • 8.4. IHC
    • 8.4.1. Direct IHC
    • 8.4.2. Indirect IHC
    • 8.4.3. Tissue Microarray
  • 8.5. Microarray
    • 8.5.1. Comparative Genomic Hybridization
    • 8.5.2. Expression Profiling
    • 8.5.3. SNP Genotyping
  • 8.6. Next Generation Sequencing
    • 8.6.1. Targeted Sequencing
      • 8.6.1.1. Amplicon Based
      • 8.6.1.2. Hybrid Capture
    • 8.6.2. Transcriptome Sequencing
    • 8.6.3. Whole Exome Sequencing
    • 8.6.4. Whole Genome Sequencing
  • 8.7. Real Time PCR
    • 8.7.1. Dye Based
    • 8.7.2. Probe Based

9. Cancer/Tumor Profiling Market, by Product Type

  • 9.1. Consumables Reagents
    • 9.1.1. Antibodies
    • 9.1.2. PCR Reagents
    • 9.1.3. Probes
    • 9.1.4. Sequencing Reagents
  • 9.2. Instruments
    • 9.2.1. Fluorescence Microscopes
    • 9.2.2. Mass Spectrometers
    • 9.2.3. Microarray Scanners
    • 9.2.4. PCR Instruments
    • 9.2.5. Sequencers
  • 9.3. Software & Services
    • 9.3.1. Bioinformatics Software
    • 9.3.2. Cloud Platforms
    • 9.3.3. Consultation Services
    • 9.3.4. Data Management Systems

10. Cancer/Tumor Profiling Market, by Application

  • 10.1. Breast Cancer
    • 10.1.1. Gene Expression Profiling
    • 10.1.2. Genetic Mutation Detection
    • 10.1.3. Proteomic Profiling
    • 10.1.4. Receptor Profiling
  • 10.2. Colorectal Cancer
    • 10.2.1. Epigenetic Profiling
    • 10.2.2. MSI Testing
    • 10.2.3. Mutation Analysis
  • 10.3. Lung Cancer
    • 10.3.1. Minimal Residual Disease Monitoring
    • 10.3.2. Molecular Susceptibility Testing
    • 10.3.3. Therapy Selection
  • 10.4. Prostate Cancer
    • 10.4.1. Copy Number Variation Analysis
    • 10.4.2. Fusion Detection
    • 10.4.3. Gene Expression Analysis

11. Cancer/Tumor Profiling Market, by End User

  • 11.1. Diagnostic Laboratories
    • 11.1.1. Clinical Laboratories
    • 11.1.2. Reference Laboratories
  • 11.2. Hospitals Clinics
    • 11.2.1. Oncology Departments
    • 11.2.2. Pathology Labs
  • 11.3. Pharma & Biopharma Companies
    • 11.3.1. Clinical Trial Units
    • 11.3.2. Companion Diagnostic Services
    • 11.3.3. Drug Development Divisions
  • 11.4. Research & Academic Institutes
    • 11.4.1. Biotech Research Centers
    • 11.4.2. Government Research Institutes
    • 11.4.3. University Research Labs

12. Cancer/Tumor Profiling Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Cancer/Tumor Profiling Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Cancer/Tumor Profiling Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Thermo Fisher Scientific Inc.
    • 15.3.2. Illumina, Inc.
    • 15.3.3. F. Hoffmann-La Roche Ltd
    • 15.3.4. QIAGEN N.V.
    • 15.3.5. Agilent Technologies, Inc.
    • 15.3.6. Bio-Rad Laboratories, Inc.
    • 15.3.7. PerkinElmer, Inc.
    • 15.3.8. Guardant Health, Inc.
    • 15.3.9. Natera, Inc.
    • 15.3.10. NeoGenomics, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS CANCER/TUMOR PROFILING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. CANCER/TUMOR PROFILING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. CANCER/TUMOR PROFILING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CANCER/TUMOR PROFILING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CONVENTIONAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CONVENTIONAL PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CONVENTIONAL PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CONVENTIONAL PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CONVENTIONAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CONVENTIONAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DIGITAL PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY FISH, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY FISH, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY FISH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY FISH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY FISH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY FISH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY FISH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY FISH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CHROMOSOME ENUMERATION PROBES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CHROMOSOME ENUMERATION PROBES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CHROMOSOME ENUMERATION PROBES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CHROMOSOME ENUMERATION PROBES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CHROMOSOME ENUMERATION PROBES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CHROMOSOME ENUMERATION PROBES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COPY NUMBER VARIATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COPY NUMBER VARIATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COPY NUMBER VARIATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COPY NUMBER VARIATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COPY NUMBER VARIATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COPY NUMBER VARIATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY FUSION GENE DETECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY FUSION GENE DETECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY FUSION GENE DETECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY FUSION GENE DETECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY FUSION GENE DETECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY FUSION GENE DETECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY IHC, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY IHC, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY IHC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY IHC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY IHC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY IHC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY IHC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY IHC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DIRECT IHC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DIRECT IHC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DIRECT IHC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DIRECT IHC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DIRECT IHC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DIRECT IHC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY INDIRECT IHC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY INDIRECT IHC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY INDIRECT IHC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY INDIRECT IHC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY INDIRECT IHC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY INDIRECT IHC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TISSUE MICROARRAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TISSUE MICROARRAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TISSUE MICROARRAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TISSUE MICROARRAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TISSUE MICROARRAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TISSUE MICROARRAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY EXPRESSION PROFILING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY EXPRESSION PROFILING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY EXPRESSION PROFILING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY EXPRESSION PROFILING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY EXPRESSION PROFILING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY EXPRESSION PROFILING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SNP GENOTYPING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SNP GENOTYPING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SNP GENOTYPING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SNP GENOTYPING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SNP GENOTYPING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SNP GENOTYPING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TARGETED SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TARGETED SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY AMPLICON BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY AMPLICON BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY AMPLICON BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY AMPLICON BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY AMPLICON BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY AMPLICON BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY HYBRID CAPTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY HYBRID CAPTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY HYBRID CAPTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY HYBRID CAPTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY HYBRID CAPTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY HYBRID CAPTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TRANSCRIPTOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TRANSCRIPTOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TRANSCRIPTOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TRANSCRIPTOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TRANSCRIPTOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY TRANSCRIPTOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY REAL TIME PCR, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY REAL TIME PCR, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY REAL TIME PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY REAL TIME PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DYE BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DYE BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DYE BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DYE BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DYE BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DYE BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROBE BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROBE BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROBE BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROBE BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROBE BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROBE BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CONSUMABLES REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CONSUMABLES REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CONSUMABLES REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CONSUMABLES REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CONSUMABLES REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CONSUMABLES REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CONSUMABLES REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PCR REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PCR REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PCR REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PCR REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PCR REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PCR REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROBES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROBES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROBES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROBES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROBES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROBES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SEQUENCING REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SEQUENCING REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SEQUENCING REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SEQUENCING REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SEQUENCING REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SEQUENCING REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY FLUORESCENCE MICROSCOPES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY FLUORESCENCE MICROSCOPES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY FLUORESCENCE MICROSCOPES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY FLUORESCENCE MICROSCOPES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY FLUORESCENCE MICROSCOPES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY FLUORESCENCE MICROSCOPES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MASS SPECTROMETERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MASS SPECTROMETERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MASS SPECTROMETERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MASS SPECTROMETERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MASS SPECTROMETERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MASS SPECTROMETERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAY SCANNERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAY SCANNERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAY SCANNERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAY SCANNERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAY SCANNERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY MICROARRAY SCANNERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PCR INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PCR INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PCR INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PCR INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PCR INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PCR INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SEQUENCERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SEQUENCERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SEQUENCERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SEQUENCERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SEQUENCERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SEQUENCERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOINFORMATICS SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOINFORMATICS SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOINFORMATICS SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOINFORMATICS SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOINFORMATICS SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BIOINFORMATICS SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CLOUD PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CLOUD PLATFORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CLOUD PLATFORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CLOUD PLATFORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CLOUD PLATFORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CLOUD PLATFORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CONSULTATION SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CONSULTATION SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CONSULTATION SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CONSULTATION SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CONSULTATION SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CONSULTATION SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DATA MANAGEMENT SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DATA MANAGEMENT SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DATA MANAGEMENT SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DATA MANAGEMENT SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DATA MANAGEMENT SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY DATA MANAGEMENT SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BREAST CANCER, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BREAST CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY GENE EXPRESSION PROFILING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY GENE EXPRESSION PROFILING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY GENE EXPRESSION PROFILING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY GENE EXPRESSION PROFILING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY GENE EXPRESSION PROFILING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY GENE EXPRESSION PROFILING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY GENETIC MUTATION DETECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY GENETIC MUTATION DETECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY GENETIC MUTATION DETECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY GENETIC MUTATION DETECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY GENETIC MUTATION DETECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY GENETIC MUTATION DETECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROTEOMIC PROFILING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROTEOMIC PROFILING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROTEOMIC PROFILING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROTEOMIC PROFILING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROTEOMIC PROFILING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY PROTEOMIC PROFILING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY RECEPTOR PROFILING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY RECEPTOR PROFILING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY RECEPTOR PROFILING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY RECEPTOR PROFILING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY RECEPTOR PROFILING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY RECEPTOR PROFILING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 301. GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY COLORECTAL CANCER, 2018-2024 (USD MILLION)
  • TABLE 302. GLOBAL CANCER/TUMOR PROFILING MA